Following this approval for Enhertu in the US, an amount of $175 million is due from AstraZeneca to Daiichi Sankyo as a milestone payment and will be capitalised as an addition to the upfront payment of $1.5 billion made by AstraZeneca to Daiichi Sankyo in 2019. Read more: https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/astrazenecas-breast-cancer-drug-secures-fda-approval-company-to-pay-175-mn-to-japanese-partner/117621184